高海拔地区2型糖尿病合并勃起功能障碍患者的临床治疗探索

发布时间：2018-06-28 17:26

  本文选题：高海拔地区 + 勃起功能障碍　； 参考：《中华男科学杂志》2017年10期

【摘要】：目的:探讨胰激肽原酶肠溶片联合西地那非治疗高海拔地区2型糖尿病合并勃起功能障碍(ED)患者的安全性及疗效。方法:选择青海西宁地区糖尿病合并ED患者93例,随机分成两组,试验组(48例)服用胰激肽原酶肠溶片(120 u,3次/d)联合小剂量西地那非规律服用(25 mg,每晚1次),对照组(45例)小剂量西地那非规律服用(25 mg,每晚1次),两组治疗4、8周后评价两组阴茎彩色多普勒超声(CDDU)检查、国际勃起功能指数(IIEF-5)、性交满意度。结果:患者年龄及糖尿病病程两组间均无显著差异(P0.05)。治疗4周:试验组和对照组治疗前后IIEF-5评分[(8.81±2.06)分vs(11.54±7.72)分和(8.29±1.91)分vs(9.37±1.65)分]、SIS[(3.35±2.43)分vs(6.83±2.61)分和(3.41±2.38)分vs(4.92±2.49)分]、CDDU均有显著差异(P0.05),两组间IIEF-5评分[(11.54±7.72)分vs(9.37±1.65)分]和SIS[(6.83±2.61)分vs(4.92±2.49)分]有显著差异(P0.05),而CDDU参数无差异(P0.05)。治疗8周:试验组和对照组治疗前后IIEF-5评分[(8.81±2.06)分vs(19.29±1.85)分和(8.29±1.91)分vs(15.43±1.74)分]均有显著差异(P0.05),两组间IIEF-5评分[(19.29±1.85)分vs(15.43±1.74)分]、SIS[(11.73±2.57)分vs(6.55±2.71)分]、CDDU参数均有显著差异(P0.05)。结论:胰激肽原酶肠溶片联合西地那非治疗高海拔地区2型糖尿病合并ED患者具有一定临床疗效,且较单一西地那非治疗更为有效。
[Abstract]:Objective: to investigate the safety and efficacy of pancreatic kallikrein enteric-coated tablets combined with sildenafil in the treatment of type 2 diabetes mellitus with erectile dysfunction (Ed) at high altitude. Methods: 93 diabetic patients with Ed in Xining district of Qinghai province were randomly divided into two groups. The trial group (48 cases) received pancreatic kallikinase enteric-coated tablets (120 UU / d) combined with low-dose sildenafil (25 mg once a night), the control group (45 cases) received low-dose sildenafil regularly (25 mg, once a night), and the two groups were treated for 48 weeks. After evaluation, two groups of penis color Doppler ultrasound (CDDU) were examined. International erectile function Index (IIEF-5), sexual satisfaction. Results: there was no significant difference in age and course of diabetes between the two groups (P0.05). 娌荤枟4鍛，

本文编号：2078778